AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03582215
Drug: Part 2: Pump Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Approximately 2 mg per cm2 of body surface will be applied topically 1 time on day 1 and 4 times per day on following 3 days to approximately 75% of the body surface area
Trial: NCT02163902
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical evaluation, patient reported outcome questionnaires, photographs, caliper measurements, recording of adverse events
Trial: NCT00992706
Drug: antiperspirant cream F511
RxNorm normalized name: DEODORANTS/ANTIPERSPIRANTS,TOPICAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo and verum cream once daily, in the morning, during the first week of the first PLD treatment only, then once daily, three times per week (in the morning). Tube R for right hand and foot, tube L for left hand and foot.
Trial: NCT03954639
Drug: EXPAREL 13.3Mg/mL Suspension for Injection
RxNorm normalized name: EXPAREL 13.3mg/mL Suspension for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined Sciatic and Adductor Canal Nerve Block with EXPAREL mixed with Bupivacaine (Single Dose)
Trial: NCT01140308
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomization to Treatment: Simvastatin 20mg + Placebo 600mg Load Subjects for 2 weeks on Treatment Eight weeks of treatment
Trial: NCT04244448
Drug: receive dissolved form of BIKTARVY®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The healthy volunteers will receive dissolved form of BIKTARVY® Pharmacokinetic samples will be taken at the following times: 0 hour (right before taking Biktarvy®); 0.5 hour; 1 hour; 1.5 hours; 2 hours; 2.5 hours; 3 hours; 4 hours; 8 hours; 12 hours; 24 hours; 36 hours; 48 hours and 72 hours (after Biktarvy®).
Trial: NCT04244448
Drug: receive crushed form of BIKTARVY®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The healthy volunteers will receive crushed form of BIKTARVY® Pharmacokinetic samples will be taken at the following times: 0 hour (right before taking Biktarvy®); 0.5 hour; 1 hour; 1.5 hours; 2 hours; 2.5 hours; 3 hours; 4 hours; 8 hours; 12 hours; 24 hours; 36 hours; 48 hours and 72 hours (after Biktarvy®).
Trial: NCT04244448
Drug: receive solid form of BIKTARVY®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The healthy volunteers will receive solid form of BIKTARVY® Pharmacokinetic samples will be taken at the following times: 0 hour (right before taking Biktarvy®); 0.5 hour; 1 hour; 1.5 hours; 2 hours; 2.5 hours; 3 hours; 4 hours; 8 hours; 12 hours; 24 hours; 36 hours; 48 hours and 72 hours (after Biktarvy®).
Trial: NCT00992706
Drug: pegylated liposomal doxorubicin hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: According to local practice. 1, 2 and 4 week schedules with at least 10mg/m2 per week are allowed.
Trial: NCT02511665
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given placebo
Trial: NCT01542632
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo subcutaneous injection
Trial: NCT01542632
Drug: New Formulation Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New Formulation placebo subcutaneous injection
Trial: NCT00777582
Drug: AZD2281
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral single dose formulation
Trial: NCT04352686
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of placebo to assess differences in esophageal sensitivity
Trial: NCT04494256
Drug: BIIB105
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as specified in the treatment arm.
Trial: NCT04494256
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as specified in the treatment arm.
Trial: NCT01033240
Drug: CS-1008 2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On a once a week basis CS-1008 will be administered intravenously starting at 2 mg/kg.
Trial: NCT01033240
Drug: CS-1008 6/2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A 6 mg/kg loading dose of CS-1008 will be administered intravenously, followed by a 2 mg/kg/week maintenance dose on a once-a-week basis.
Trial: NCT01033240
Drug: CS-1008 6/6 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A 6 mg/kg loading dose of CS-1008 will be administered intravenously, followed by a 6 mg/kg/week maintenance dose on a once-a-week basis.
Trial: NCT01033240
Drug: CS-1008 4 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On a once a week basis CS-1008 will be administered intravenously at 4 mg/kg if tolerated.
Trial: NCT01033240
Drug: CS-1008 6 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On a once a week basis CS-1008 will be administered intravenously at 6 mg/kg if tolerated.
Trial: NCT04332822
Drug: R-pola-mini-CHP
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Rituximab 375 mg/m2 iv, day 1, cycle 1. 1400 mg s c OR 375 mg/m2 iv cycles 2-6~* Cyclophosphamide 400 mg/m2 iv, day 1, cycles 1-6~* Doxorubicin 25 mg/m2 iv , day 1, cycles 1-6~* Prednisone, 40 mg/m2 po, days 1-5, cycles 1-6 - round up to nearest 25 mg~* Polatuzumab vedotin 1.8 mg/kg iv day 1 cycles 1-6
Trial: NCT04332822
Drug: R-mini-CHOP
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Rituximab 375 mg/m2 i.v., day 1, cycle 1. 1400 mg s c OR 375 mg/m2 i. v. cycles 2-6~* Cyclophosphamide 400 mg/m2 i.v., day 1, cycles 1-6~* Doxorubicin 25 mg/m2 i.v., day 1, cycles 1-6~* Vincristine 1 mg i.v. (total dose), day 1, cycles 1-6~* Prednisone, 40 mg/m2 p.o, days 1-5, , cycles 1-6
Trial: NCT04295317
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 2500mg / m2/ d, 2 times/d for 2 weeks, followed by 1 week of stopping ,Three weeks is a course of treatment with a total of 8 courses, or the patient has tumor recurrence or metastasis (requires imaging to determine tumor recurrence or metastasis)
Trial: NCT01035216
Drug: GNKG168
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GNKG168 will be administered as a 60 minute IV infusion once daily for 5 days followed by a 9 day rest period.
Trial: NCT04145349
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered orally
Trial: NCT03838185
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of corn oil
Trial: NCT01815723
Drug: FP187 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FP187 matching placebo tablets in the same regimen as for FP187 arm
Trial: NCT01815723
Drug: Fumaderm® placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fumaderm® matching placebo tablets in the same regimen as for Fumaderm® arm
Trial: NCT01904760
Drug: Saline placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline 0.9% (guess as 4㎍/mL) : 0.5㎍/kg/hr infusion for 1 hour before operation is completed and 0.2-0.7㎍/kg/hr infusion continuously until 6:00am the next day
Trial: NCT01032057
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03495960
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: During the primary chemo-immunotherapy (PRIMAIN regimen, 2 courses; every 43 days) administered as induction in the PART A of the study, Methotrexate is given 3 g/m2 as infusion (0.5 g/m2 in 15 min. + 2.5 g/m2 in 3-hr infusion) on days 2, 16 \& 30
Trial: NCT01894685
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 3 grams, once daily for six months
Trial: NCT00869063
Drug: Diclofenac Sodium Patch
RxNorm normalized name: diclofenac sodium Medicated Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 1% diclofenac sodium patch, applied once daily for 7 days
Trial: NCT00869063
Drug: Matching Placebo Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo patch, containing identical constituents to the active drug arm except for diclofenac sodium; applied once daily for 7 days
Trial: NCT03568422
Drug: CFI-402257
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally taken on intermittent schedule (days 1, 2, 8, 9, 15 \& 16
Trial: NCT01096966
Drug: Placebo patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identical in size and shape to the Bupivacaine Patch. Three patches applied to the lower back every 72 hours for 12 weeks.
Trial: NCT02631603
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administer Placebo as anti-inflammatory
Trial: NCT02631603
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administer Prednisolone as anti-inflammatory
Trial: NCT00002643
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002643
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02995018
Drug: BAY987521
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z09-174)
Trial: NCT02995018
Drug: SPF Control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
Trial: NCT04219826
Drug: Placebo for CK-3773274
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered orally
Trial: NCT01143298
Drug: LEO 27847 oral solution
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00688896
Drug: JTT-705 600 mg and pravastatin 40 mg
RxNorm normalized name: pravastatin and ezetimibe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * JTT-705 300 mg tablets, 600 mg dose, 2 tablets, oral, once daily, immediately following breakfast and/or assessment~* Pravastatin 40 mg tablets, 40 mg dose, one tablet, oral, once daily, at bedtime
Trial: NCT00688896
Drug: JTT-705 300 mg and pravastatin 40 mg
RxNorm normalized name: pravastatin and ezetimibe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * JTT-705 300 mg tablets, 300 mg dose, 1 tablet, oral, once daily, immediately following breakfast and/or assessment~* Placebo tablets, one tablet, oral, once daily, immediately following breakfast and/or assessments~* Pravastatin 40 mg tablets, 40 mg dose, one tablet, oral, once daily, at bedtime
Trial: NCT00688896
Drug: Placebo and pravastatin 40 mg
RxNorm normalized name: pravastatin and ezetimibe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Placebo tablets, 2 tablets, oral, once daily, immediately following breakfast and/or assessments~* Pravastatin 40 mg tablets, 40 mg dose, one tablet, oral, once daily, at bedtime
Trial: NCT05288816
Drug: ALXN1210
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received a single dose (400 mg or 800 mg) and multiple doses (800 mg) of ALXN1210.
Trial: NCT00868634
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000 mg/m2 twice daily, oral, days 1-14. Cycles are repeated every three weeks.
Trial: NCT02135848
Drug: GSK1278863
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK1278863
Trial: NCT02135848
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03977363
Drug: Anticoagulant drugs
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticoagulant drugs
Trial: NCT03602612
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 300 mg/m\^2 intravenous (IV) over 30 minutes on days -5, -4, and -3
Trial: NCT03143153
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Specified dose on specified days
Trial: NCT01323582
Drug: Erythromycin
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200mg/5ml elixir administered orally three times a day half an hour prior to meals.
Trial: NCT01323582
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The dose of Azithromycin given was determined based on the following study on 10 healthy subjects. In random order, each of ten healthy subjects underwent OBT studies following administration of AZI, at doses of 50mg, 100mg, and 133mg. The T½ and Tlag was then compared for the three doses by a randomized block analysis using Analysis of Variance followed by Tukey's multiple comparison. Results: The T½ for each of the respective doses of AZI (50mg, 100mg, and 133mg) was 129 ± 27, 128 ± 31, and 128 ± 16 minutes (p = 0.98). This data suggested that AZI at doses of 50mg, 100mg and 133 mg have fairly similar activity in its effects on gastric emptying in healthy subjects. Based on this analysis , we decided to use a dose of 50 mg/5 ml for administered TID prior to meals.
Trial: NCT01828177
Drug: PDI-320
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01828177
Drug: PDI-320 Monad #1
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01828177
Drug: PDI-320 Monad #2
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01828177
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04043455
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olorinab matching placebo capsule or tablet by mouth, 3 times per day up to 12 weeks
Trial: NCT00591006
Drug: Phenytoin (brand name Dilantin)
RxNorm normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Three days prior to imaging, participants will take two capsules containing phenytoin tablets (100 mg) by mouth at 0900 hours and 2100 hours (400 mg/day) for a total of three days with the last dose at 0900 hours on the day of the imaging (7 doses total).
Trial: NCT00591006
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Beginning two days prior to the imaging (the day after initiating the phenytoin or placebo), participants will begin taking 4 tablets containing hydrocortisone (20 mg) or placebo also at 0900 hours and 2100 hours (160 mg/day) with the last dose at 0900 hours on the day of the imaging (5 doses total). The doses were selected to achieve a low therapeutic blood level of phenytoin and stress level of cortisol. Newcomer et al. (1999) used this dose of hydrocortisone in healthy controls. The imaging will be performed at approximately 1300 hours.
Trial: NCT00591006
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants take two capsules of placebo 100 mg at 0900 hours and 2100 hours for a total of 3 days with the last dose at 0900 hours on the day of imaging (7 doses total). Beginning two days prior to the imaging (the day after initiating placebo), participants will being taking 4 tablets containing placebo (20 mg) also at 0900 hours and 2100 hours with the last dose at 0900 hours on the day of the imaging (5 doses total).
Trial: NCT03018028
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration once daily
Trial: NCT00611351
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00564681
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injections of placebo (normal saline) into the affected muscles for treatment cycle 1.
Trial: NCT03669263
Drug: Fentanyl buccal soluble film (FBSF)
RxNorm normalized name: fentanyl Buccal Film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After screening, eligible subjects were individually titrated to an adequate dose of FBSF (titration period) and continued on this dose as required to control their BTP throughout the maintenance period of the study.~During the dose titration period, subjects were administered with FBSF in a dose escalation manner until a treatment dose was identified (defined as an adequate relief of BTP observed for at least two consecutive episodes). All patient started with a dose of 200 μg and increased by 200 μg in each subsequent episode until an adequate pain relief with tolerable side effects was achieved. Doses above 1200 μg were not allowed.
Trial: NCT02181335
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02327546
Drug: AKB-6548
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01563224
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT00644033
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo tablet administered for 6 days, starting 2 days before the anticipated onset of a MAM headache.
Trial: NCT03779048
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study medication (placebo or phentermine 15.0 mg) is a once-daily self-administered pill.
Trial: NCT02460900
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00702741
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular injection of Hyaluronan
Trial: NCT01171859
Drug: Doxycycline + Tauroursodeoxycholic acid
RxNorm normalized name: Tauroursodeoxycholic acid
DrugBank: Tauroursodeoxycholic acid (DB08834)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: doxycycline 100 mg twice a day for 12 months; tauroursodeoxycholic acid 250 mg three times a day for 12 months
Trial: NCT04757506
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02655315
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the placebo twice daily morning and evening. The treatment lasts nine months
Trial: NCT02819921
Drug: Desvenlafaxine succinate 100mg
RxNorm normalized name: Desvenlafaxine
DrugBank: Desvenlafaxine (DB06700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pristiq 100mg
Trial: NCT02819921
Drug: Desvenlafaxine succinate 50mg
RxNorm normalized name: Desvenlafaxine
DrugBank: Desvenlafaxine (DB06700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pristiq 50mg
Trial: NCT02819921
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00005780
Drug: EPOCH-R
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPOCH-R for 6 cycles
Trial: NCT03258502
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo in capsules
Trial: NCT02883569
Drug: ibuprofen, naxoprofen, Cox-2 inhibitor, aceclofenac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FDA approved medication such as ibuprofen, naxoprofen etc.
Trial: NCT00240123
Drug: Benadryl versus Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01271777
Drug: GFT505 80mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hard gelatin capsules dosed at 20mg, oral administration, 4 capsules per day before breakfast
Trial: NCT01271777
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hard gelatin capsules, oral administration, 4 capsules per day before breakfast
Trial: NCT02132416
Drug: Opioids
RxNorm normalized name: OPIOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initially intravenous administration and when tolerated oral slow-release pils will be used.
Trial: NCT02621021
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day over 1 hour X 2 days.
Trial: NCT04225598
Drug: CAM2038
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive a 24 mg dose of injectable CAM2038 in the ED on Day 0.
Trial: NCT00006016
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given transarterially (chemoembolization)
Trial: NCT00003606
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01987609
Drug: Hylenex
RxNorm normalized name: Hylenex
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01987609
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01393561
Drug: Group 1
RxNorm normalized name: Chlamydophila psittaci biogroup 1 Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brompheniramine + phenylephrine
Trial: NCT01393561
Drug: Group 2
RxNorm normalized name: Chlamydophila psittaci biogroup 2 Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01899729
Drug: IMO-8400 Regimen 1
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IMO-8400 0.075 mg/kg q wk x 12 wk by subcutaneous injection
Trial: NCT01899729
Drug: IMO-8400 Regimen 2
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IMO-8400 0.15 mg/kg q wk x 12 wk by subcutaneous injection
Trial: NCT01899729
Drug: IMO-8400 Regimen 3
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IMO-8400 0.3 mg/kg q wk x 12 wk by subcutaneous injection
Trial: NCT01899729
Drug: Saline Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline q wk x 12 wk by subcutaneous injection